SITC Archive Library

iSBTc 22nd Annual Meeting Workshop 

02-21-2018 16:15

The International Society for Biological Therapy of Cancer (iSBTc) 22nd Annual Meeting: Workshop
November 1, 2007
Seaport World Trade Center in Boston, Massachusetts

Program Organizers
Bernard A. Fox, PhD - Earle A. Chiles Research Institute
Thomas F. Gajewski, MD, PhD - University of Chicago
Rachel W. Humphrey, MD - Bristol Myers-Squibb Company
Hyam I. Levistsky, MD - Johns Hopkins University, School of Medicine
Jon M. Wigginton, MD - Merck & Co., Inc

Program Summary
Drawing on dialogue initiated among leaders in the field at a highly successful planning workshop sponsored by iSBTc in 2006, this in-depth program provides an assessment of state-of-the-art opportunities for combining immune-stimulating agents with other cancer biologics as well as conventional antineoplastic agents. This highly interactive program will provide a venue for intensive scientific dialogue among key stakeholders regarding both strategic opportunities and central obstacles to realizing the potential of combination approaches for the biological therapy of cancer.

Intended Audience
The target audience for the workshop incorporates basic and clinical investigators from academic, regulatory, and biopharmaceutical venues. The audience includes, researchers, clinicians, post-doctoral fellows, students, and allied health professionals.

Presentations and video recordings are available based on permission from presenters.


#ProstateCancer #PresentationSlides #AnnualMeeting #AdoptiveCellTherapy #CombinationTherapy #Cytokines #ImmuneCheckpointInhibitors #Vaccines #Clinician #Industry #Oncologist #Researcher #2007#AlliedHealth #SITC #ClinicalTrials​ #Melanoma #AdverseEvents #Ipilimumab

Statistics
0 Favorited
19 Views
15 Files
0 Shares
19 Downloads
Attachment(s)
pdf file
Welcome and Meeting Introductions   40 KB   1 version
Uploaded - 02-21-2018
Meeting: iSBTc 22nd Annual Meeting - Workshop on Future Opportunities for Combination Biological Therapy of Cancer; Presentation: Welcome and Meeting Introductions; Presenter: Jon M. Wigginton, MD - Merck & Co., Inc; Date: Thursday, November 1, 2007
pdf file
Immunotherapy and Immunotherapy Combinations   971 KB   1 version
Uploaded - 02-21-2018
Meeting: iSBTc 22nd Annual Meeting - Workshop on Future Opportunities for Combination Biological Therapy of Cancer; Presentation: Immunotherapy and Immunotherapy Combinations; Presenter: Thomas F. Gajewski, MD, PhD - University of Chicago and Jon M. Wigginton, MD - Merck & Co., Inc; Date: Thursday, November 1, 2007
pdf file
Angiogenesis and Immunotherapy Combinations   960 KB   1 version
Uploaded - 02-21-2018
Meeting: iSBTc 22nd Annual Meeting - Workshop on Future Opportunities for Combination Biological Therapy of Cancer; Presentation: Angiogenesis and Immunotherapy Combinations; Presenter: George Coukos, MD, PhD - University of Pennsylvania Medical Center and Heinz Zwierzina, MD - Innsbruck Medical University; Date: Thursday, November 1, 2007
pdf file
Apoptosis Induction and Immunotherapy   3.82 MB   1 version
Uploaded - 02-21-2018
Meeting: iSBTc 22nd Annual Meeting - Workshop on Future Opportunities for Combination Biological Therapy of Cancer; Presentation: Apoptosis Induction and Immunotherapy; Presenter: James H. Finke, PhD - Cleveland Clinic Foundation and Peter Hersey, MD, PhD - University of Newcastle; Date: Thursday, November 1, 2007
pdf file
Cytotoxic Chemotherapy and Immunotherapy   888 KB   1 version
Uploaded - 02-21-2018
Meeting: iSBTc 22nd Annual Meeting - Workshop on Future Opportunities for Combination Biological Therapy of Cancer; Presentation: Cytotoxic Chemotherapy and Immunotherapy; Presenter: Hyam I. Levitsky, MD - Johns Hopkins University School of Medicine and Ronald E. Gress, MD - NCI, NIH; Date: Thursday, November 1, 2007
pdf file
Anti-PD-1 Antibody Enhances the Potency of GM-CSF Secreti...   160 KB   1 version
Uploaded - 02-21-2018
Meeting: iSBTc 22nd Annual Meeting - Workshop on Future Opportunities for Combination Biological Therapy of Cancer; Presentation: Anti-PD-1 Antibody Enhances the Potency of GM-CSF Secreting Tumor Cell Immunotherapy by Augmenting Immunotherapy-Induced Tumor Specific T-Cell Responses; Presenter: Betty Li - Cell Genesys, Inc; Date: Thursday, November 1, 2007
pdf file
Cyclophosphamide and Fludarabine Treatment Prior to Recon...   694 KB   1 version
Uploaded - 02-21-2018
Meeting: iSBTc 22nd Annual Meeting - Workshop on Future Opportunities for Combination Biological Therapy of Cancer; Presentation: Cyclophosphamide and Fludarabine Treatment Prior to Reconstitution with PBMC Does Not Reduce the Frequency of Circulating FoxP3+ Cells in Vaccinated Prostate Cancer Patients; Presenter: James Thompson, MD - Earle A. Chiles Research Institute; Date: Thursday, November 1, 2007
pdf file
C), and Extracellular ATP in Murine Models   597 KB   1 version
Uploaded - 02-21-2018
Meeting: iSBTc 22nd Annual Meeting - Workshop on Future Opportunities for Combination Biological Therapy of Cancer; Presentation: Treatment of Established Tumors with Peritumoral Injections of CD40 Lingand (CD40L), CpG, poly(I:C), and Extracellular ATP in Murine Models; Presenter: Richard S. Kornbluth, MD, PhD - University of California San Diego; Date: Thursday, November 1, 2007
pdf file
Perspectives on Combination Therapy - Regulatory Perspec...   340 KB   1 version
Uploaded - 02-21-2018
Meeting: iSBTc 22nd Annual Meeting - Workshop on Future Opportunities for Combination Biological Therapy of Cancer; Presentation: Plenary Session: Perspectives on Combination Therapy - Regulatory Perspective ; Presenter: Ashok Batra, MD - Food and Drug Administration; Date: Thursday, November 1, 2007
pdf file
Perspectives on Combination Therapy - Industry Perspective   305 KB   1 version
Uploaded - 02-21-2018
Meeting: iSBTc 22nd Annual Meeting - Workshop on Future Opportunities for Combination Biological Therapy of Cancer; Presentation: Plenary Session: Perspectives on Combination Therapy - Industry Perspective; Presenter: Geoffrey Nichol, MBChB, MBA - Medarex, Inc.; Date: Thursday, November 1, 2007
pdf file
Perspectives on Combination Therapy - Legal Perspective   61 KB   1 version
Uploaded - 02-21-2018
Meeting: iSBTc 22nd Annual Meeting - Workshop on Future Opportunities for Combination Biological Therapy of Cancer; Presentation: Plenary Session: Perspectives on Combination Therapy - Legal Perspective; Presenter: Andrew D. Barofsky, JD, MBA - Oregon Biomedical Engineering Institute, Inc.; Date: Thursday, November 1, 2007
pdf file
Immunotherapy and Immunotherapy Combinations   21 KB   1 version
Uploaded - 02-21-2018
Meeting: iSBTc 22nd Annual Meeting - Workshop on Future Opportunities for Combination Biological Therapy of Cancer; Presentation: Breakout Report 1: Immunotherapy and Immunotherapy Combinations; Presenter: Jon M. Wigginton, MD - Merck & Co., Inc; Date: Thursday, November 1, 2007
pdf file
Angiogensesis and Immunotherapy Combinations   22 KB   1 version
Uploaded - 02-21-2018
Meeting: iSBTc 22nd Annual Meeting - Workshop on Future Opportunities for Combination Biological Therapy of Cancer; Presentation: Breakout Report 2: Angiogensesis and Immunotherapy Combinations; Presenter: heinz Zwierzina, MD - Innsbrack Medical University; Date: Thursday, November 1, 2007
pdf file
Apoptosis Induction and Immunotherapy   20 KB   1 version
Uploaded - 02-21-2018
Meeting: iSBTc 22nd Annual Meeting - Workshop on Future Opportunities for Combination Biological Therapy of Cancer; Presentation: Breakout Report 2: Breakout Report 3: Apoptosis Induction and Immunotherapy; Presenter: James H. Finke, PhD - Cleveland Clinic Foundation; Date: Thursday, November 1, 2007
pdf file
Cytotoxic Chemotherapy and Immunotherapy   20 KB   1 version
Uploaded - 02-21-2018
Meeting: iSBTc 22nd Annual Meeting - Workshop on Future Opportunities for Combination Biological Therapy of Cancer; Presentation: Breakout Report 4: Cytotoxic Chemotherapy and Immunotherapy; Presenter: Ronald E. Gress, MD - NCI/NIH; Date: Thursday, November 1, 2007